Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)

2017 2018 Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6 Hammel, 2016, Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial, JAMA, 315, 1844, 10.1001/jama.2016.4324 de Geus, 2017 Khorana, 2016, Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 34, 2541, 10.1200/JCO.2016.67.5553 Brown, 2014, The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved?, Int J Radiat Oncol Biol Phys, 88, 254, 10.1016/j.ijrobp.2013.07.022 Ball, 2017, MA 13.07 A randomized trial of SABR vs conventional radiotherapy for inoperable stage I non-small cell lung cancer: TROG09. 02 (CHISEL), J Thorac Oncol, 12, S1853, 10.1016/j.jtho.2017.09.565 Foote, 2011, Technique for stereotactic body radiotherapy for spinal metastases, J Clin Neurosci, 18, 276, 10.1016/j.jocn.2010.04.033 Russo, 2018 Goodman, 2012, Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer, Int J Radiat Oncol Biol Phys, 83, 901, 10.1016/j.ijrobp.2012.01.022 Caravatta, 2012, Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer, Radiat Oncol, 7, 86, 10.1186/1748-717X-7-86 Fairchild, 2013, Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review, Int J Radiat Oncol Biol Phys, 87, 246, 10.1016/j.ijrobp.2013.03.036 Weber, 2012, QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy, Radiother Oncol, 105, 4, 10.1016/j.radonc.2012.08.008 Katz, 2017, Alliance for clinical trials in oncology (ALLIANCE) trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas, BMC Cancer, 17, 505, 10.1186/s12885-017-3441-z Lee, 2009, Phase I study of individualized stereotactic body radiotherapy of liver metastases, J Clin Oncol, 27, 1585, 10.1200/JCO.2008.20.0600 Wahl, 2016, Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma, J Clin Oncol, 34, 452, 10.1200/JCO.2015.61.4925 Mellon, 2015, Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma, Acta Oncol, 54, 979, 10.3109/0284186X.2015.1004367 Petrelli, 2017, stereotactic body radiation therapy for locally advanced pancreatic cancer: A systematic review and pooled analysis of 19 trials, Int J Radiat Oncol Biol Phys, 97, 313, 10.1016/j.ijrobp.2016.10.030 Blair, 2018, Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy, Surgery, 163, 1090, 10.1016/j.surg.2017.11.027 Dholakia, 2013, Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships, J Radiat Oncol, 2, 413, 10.1007/s13566-013-0115-6 Chuong, 2013, Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated, Int J Radiat Oncol Biol Phys, 86, 516, 10.1016/j.ijrobp.2013.02.022 Palta, 2016, Interim acute toxicity analysis and surgical outcomes of neoadjuvant gemcitabine/nab-paclitaxel and hypofractionated image guided intensity modulated radiation therapy in resectable and borderline resectable pancreatic cancer (ANCHOR) study, Int J Radiat Oncol Biol Phys, 96, S204, 10.1016/j.ijrobp.2016.06.509 Kim, 2019, Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia, J Med Radiat Sci, 66, 54, 10.1002/jmrs.313 Chatterjee, 2017, Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy, Am J Surg Pathol, 41, 1097, 10.1097/PAS.0000000000000887 Marchegiani, 2017, Does size matter in pancreatic cancer?: Reappraisal of tumour dimension as a predictor of outcome beyond the TNM, Ann Surg, 266, 142, 10.1097/SLA.0000000000001837 Motoi, 2019, Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05), Jpn J Clin Oncol, 49, 190, 10.1093/jjco/hyy190 Conroy, 2018, Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas, J Clin Oncol, 10.1200/JCO.2018.36.18_suppl.LBA4001 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Van Tienhoven, 2018, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial, J Clin Oncol, 10.1200/JCO.2018.36.18_suppl.LBA4002 Pollom, 2014, Single versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity, Int J Radiat Oncol Biol Phys, 90, 918, 10.1016/j.ijrobp.2014.06.066 Hoyer, 2005, Phase II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma, Radiother Oncol, 76, 48, 10.1016/j.radonc.2004.12.022 Parekh, 2017, Stereotactic body radiation for pancreatic cancer: Results of an international survey of practice patterns, J Radiat Oncol, 6, 273, 10.1007/s13566-016-0267-2 Brunner, 2015, SBRT in pancreatic cancer: What is the therapeutic window?, Radiother Oncol, 114, 109, 10.1016/j.radonc.2014.10.015 Lin, 2015, Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer, Eur J Gastroenterol Hepatol, 27, 259, 10.1097/MEG.0000000000000283 Song, 2015, Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer, Onco Targets Ther, 8, 1427, 10.2147/OTT.S81939 Su, 2015, Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer, World J Gastroenterol, 21, 8156, 10.3748/wjg.v21.i26.8156 Boone, 2013, Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer, J Surg Oncol, 108, 236, 10.1002/jso.23392 Gurka, 2017, Stereotactic body radiation therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma, Am J Clin Oncol, 40, 152, 10.1097/COC.0000000000000118 Goyal, 2012, Stereotactic body radiation therapy for nonresectable tumors of the pancreas, J Surg Res, 174, 319, 10.1016/j.jss.2011.07.044 Herman, 2012, A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.4045 Pepin, 2015, Comparison of implanted fiducial markers and self-expandable metallic stents for pancreatic image guided radiation therapy localization, Pract Radiat Oncol, 5, e193, 10.1016/j.prro.2014.08.019 Huguet, 2015, Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers, Int J Radiat Oncol Biol Phys, 91, 579, 10.1016/j.ijrobp.2014.10.058 Sanders, 2010, EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer, Gastrointest Endosc, 71, 1178, 10.1016/j.gie.2009.12.020 Choi, 2014, Fiducial placement for stereotactic body radiation therapy under only endoscopic ultrasonography guidance in pancreatic and hepatic malignancy: Practical feasibility and safety, Gut Liver, 8, 88, 10.5009/gnl.2014.8.1.88 Herman, 2015, Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma, Cancer, 121, 1128, 10.1002/cncr.29161 Heerkens, 2014, MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer, Radiother Oncol, 111, 252, 10.1016/j.radonc.2014.03.002 Bussels, 2003, Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer, Radiother Oncol, 68, 69, 10.1016/S0167-8140(03)00133-6 Feng, 2009, Characterization of pancreatic tumor motion using cine MRI: Surrogates for tumor position should be used with caution, Int J Radiat Oncol Biol Phys, 74, 884, 10.1016/j.ijrobp.2009.02.003 Godfrey, 2017, Triphasic contrast enhanced CT simulation with bolus tracking for pancreas SBRT target delineation, Pract Radiat Oncol, 7, e489, 10.1016/j.prro.2017.04.008 Hall, 2018, Pancreatic gross tumor volume contouring on computed tomography (CT) as compared with magnetic resonance imaging (MRI), results of an international contouring conference, Pract Radiat Oncol, 8, 107, 10.1016/j.prro.2017.11.005 Dholakia, 2014, Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy, Int J Radiat Oncol Biol Phys, 89, 539, 10.1016/j.ijrobp.2014.02.031 Mellon, 2017, Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy, Acta Oncol, 56, 391, 10.1080/0284186X.2016.1256497 Schellenberg, 2010, 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy, Int J Radiat Oncol Biol Phys, 77, 1420, 10.1016/j.ijrobp.2009.06.049 Heerkens, 2017, Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer, Pract Radiat Oncol, 7, 126, 10.1016/j.prro.2016.10.006 Apte, 2013, A starring role for stellate cells in the pancreatic cancer microenvironment, Gastroenterology, 144, 1210, 10.1053/j.gastro.2012.11.037 Apte, 2004, Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells, Pancreas, 29, 179, 10.1097/00006676-200410000-00002 Kharofa, 2019, Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer, Am J Clin Oncol, 42, 247, 10.1097/COC.0000000000000518 Zhu, 2019, Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design, Int J Radiat Oncol Biol Phys, 104, 101, 10.1016/j.ijrobp.2019.01.075 Baine, 2019, Incidence and patterns of locoregional failure after stereotactic body radiation therapy for pancreatic adenocarcinoma, Pract Radiat Oncol, 9, e29, 10.1016/j.prro.2018.06.006